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Beta-site amyloid-precursor-protein cleaving enzyme 1 (BACE1) is the rate limiting
protease in the production of the amyloid-beta peptide (Aβ), which is considered to
be the causative agent in the pathogenesis of Alzheimer’s Disease (AD). Therefore, the
therapeutic potential of pharmacological BACE1 inhibitors is currently tested in clinical
trials for AD treatment. To ensure a positive clinical outcome it is crucial to identify
and evaluate adverse effects associated with BACE1 inhibition. Preclinical studies show
that chronic blockade of BACE1 activity alters synaptic functions and leads to loss of
dendritic spines. To assess the mechanism of synapse loss, dendritic spine dynamics
of pyramidal layer V cells were monitored by in vivo two-photon microscopy in the
somatosensory cortex of mice, treated with the BACE1 inhibitor MK-8931. MK-8931
treatment significantly reduced levels of Aβ40 and density of dendritic spines in the
brain. However, the steady decline in dendritic spine density specifically resulted from a
diminished formation of new spines and not from a loss of stable spines. Furthermore,
the described effects on spine formation were transient and recovered after inhibitor
withdrawal. Since MK-8931 inhibition did not completely abolish spine formation, our
findings suggest that carefully dosed inhibitors might be therapeutically effective without
affecting the structural integrity of excitatory synapses if given at an early disease stage.
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INTRODUCTION
Beta-site amyloid-precursor-protein cleaving enzyme 1 (BACE1) is considered as a potential
drug target for therapeutic intervention in Alzheimer’s disease (AD) for years. According to the
amyloid-cascade-hypothesis the molecular cause of AD is the pathological accumulation and
aggregation of the amyloid-beta peptide (Aβ). BACE1 is considered to be the rate determining step
in Aβ production by initiating the amyloidogenic pathway trough cleavage of the amyloid precursor
protein (APP), which is followed by γ-secretase cleavage (Hardy and Higgins, 1992; Selkoe, 2002;
Selkoe and Hardy, 2016). Accordingly, it has been shown that BACE1 inhibition efficiently lowers
Aβ levels in the central nervous system of healthy subjects and AD patients (Forman et al., 2012;
Neumann et al., 2015; Thakker et al., 2015; Kennedy et al., 2016). These encouraging findings led
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to further evaluation of MK-8931 (Verubecestat), a
BACE1 inhibitor with good oral bioavailability and blood-
brain-barrier permeability (Forman et al., 2013).
However, the physiological role of APP cleaving enzymes
in the mature nervous system is incompletely understood
and has to be investigated in more detail. This lack of
knowledge might have contributed to the failure of the
γ-secretase inhibitor LY-450139 (Semagacestat) in clinical trials.
Prolonged treatment with LY-450139 caused worsening of
cognitive functions in AD patients as well as infections and
skin cancer (Schor, 2011) leading to early termination of
the study in clinical phase III, April 2011 (Doody et al.,
2013). Altered cognitive function during long-term γ-secretase
inhibition in humans might be associated with the preclinical
observation that treatment with LY-450139 causes a persistent
reduction in dendritic spine density in mice (Bittner et al.,
2009).
Dendritic spines are highly plastic structures which
are continuously formed and eliminated throughout life.
According to their lifetime dendritic spines can be distinguished
into two classes: Transient spines with a lifetime of less
than 4 days and stable spines which persist more than
8 days (Holtmaat et al., 2005). The structural dynamics of
dendritic spines represent a central cellular mechanism in
the formation of memory (Chklovskii et al., 2004; Holtmaat
and Svoboda, 2009; Xu et al., 2009; Yang et al., 2009). Short-
lived transient spines are associated with learning (Bourne
and Harris, 2008), whereas stable spines are associated
with long-term memory (Yang et al., 2009). Therefore,
the worsening of memory observed in the LY-450139
trial might be attributable in part to the loss of dendritic
spines.
Importantly, it has been shown recently that prolonged
treatment with BACE1 inhibitors also reduces dendritic spine
densities in wildtype mice (Filser et al., 2015; Zhu et al.,
2018). However, differential inhibitor effects on transient and
stable spine populations have not been analyzed, although
this information would provide clear implications for the
interpretation of prospective clinical outcomes.
To decipher the cause of BACE1 inhibitor induced spine
loss, we first treated mice chronically with the clinically
most advanced BACE1 inhibitor MK-8931 and confirmed
inhibitor efficacy by determining cortical Aβ levels via sandwich
ELISA. To clarify whether BACE1 inhibition leads to a
loss of stable spines or to a decrease in spine formation,
we performed long-term in vivo two-photon imaging of
transgenic mice expressing eGFP in cortical layer V pyramidal
neurons and analyzed the kinetics of spine turn-over and
stability.
As anticipated, our data showed that BACE1 plays an
important role in the regulation of structural spine plasticity.
In particular, we observed a significant but reversible
BACE1 inhibitor effect on spine formation, whereas a loss
of stable spines was not detected. Thus, pharmacological
BACE1 inhibition specifically altered dendritic spine formation
but did not disrupt substantially the structural integrity of
excitatory synapses.
MATERIALS AND METHODS
BACE1 Inhibitor
The BACE1 inhibitor MK-8931 was synthesized following the
schemes provided by FORUM Pharmaceuticals (Waltham, MA,
USA) and formulated in 10% (w/v) 2-hydroxypropyl-beta-
cyclodextrin. MK-8931 was administered at 20 mg/kg body
weight by oral gavage every 12 h for 21 days.
Animals
Female and male 3 month old heterozygous GFP-M mice
(Tg(Thy1-EGFP)MJrs from Jackson Laboratory) were used
(Feng et al., 2000). Mice were group-housed under pathogen-free
conditions and bred in the animal housing facility at the
Center for Neuropathology and Prion Research of the Ludwig-
Maximilians-University of Munich, with food and water
provided ad libitum (21± 1◦C, at 12/12 h light/dark cycle). After
cranial window implantation, mice were housed separately. All
applicable international, national and/or institutional guidelines
for the care and use of animals were followed. All experiments
were carried out in compliance with the National Guidelines for
Animal Protection, Germany with the approval of the regional
Animal care committee of the Government of Oberbayern
(Regierung Oberbayern) and were overseen by a veterinarian.
Animal experiments were conducted in accordance with the
guidelines EU Directive 2010/63/EU for animal experiments.
Aβ Purification and ELISA Assay
Cortices from C57BL/6J mice were isolated 4 h after the last
drug administration, frozen and homogenized in 1 ml of 2%
diethylamine, containing 50 mmol/L sodium chloride (pH 10),
complete protease inhibitors (Sigma-Aldrich, St. Louis, MO,
USA), and 2 mmol/L EDTA. Samples were homogenized with
a rotor-stator homogenizer, directly followed by neutralization
of the homogenate with Tris-HCl buffer, pH 6.8. Suspensions
were then centrifuged at 3500× g at 4◦C for 5 min. Supernatants
were transferred to new vials and subjected to clarifying
ultracentrifugation at 130,000× g at 4◦C for 30 min to obtain
the mass fraction of diethanolamine (DEA) fraction. Pellets from
the first centrifugation were washed with PBS to remove the
remaining soluble fraction and then lysed in STE buffer (150 mM
NaCl, 50 mM Tris-HCl, 2 mM EDTA) and 1% Triton X-100
for 60 min on ice followed by centrifugation at 20,000× g for
10 min at 4◦C. The resulting insoluble fractions were transferred
to fresh tubes. Protein concentration of insoluble or DEA
fractions wasmeasured using the (BCA)method according to the
manufacturer’s instructions (Interchim, Mannheim, Germany).
Aβ40 levels of both tissue fractions weremeasured usingMSDAβ
triplex sandwich immunoassay (MesoScale Discovery, Rockville,
MD, USA) in accordance with the protocols provided by
the manufacturer. The concentrations of Aβ40 peptide were
calculated using the MSD discovery workbench software and
normalized to protein content. Combined total normalized
Aβ40 levels of brain homogenates are displayed in the ‘‘Results’’
section.
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Cranial Window Implantation
Mice were anesthetized with an intraperitoneal injection of
ketamine/xylazine (130/10 mg/kg body weight; WDT/Bayer
Health Care) and dexamethasone (6 mg/kg body weight, Sigma)
was applied to prevent development of cerebral edema. A circular
piece of the skull (3 mm in diameter) over the somatosensory
cortex (coordinates of craniotomy: Bregma +1.5 to −3.5 mm,
3 mm lateral from midline) was removed and replaced with
a cranial window, as described before (Fuhrmann et al., 2007;
Holtmaat et al., 2009). In addition, a metal bar was attached to
the skull to allow repositioning of the mouse during subsequent
imaging sessions. After surgery, mice received subcutaneously
antibiotic Cefotaxim (2.5 mg/kg body weight; Pharmore) and
Rimadyl (7.5 mg/kg body weight).
In Vivo Two-Photon Imaging
After a recovery period of 4 weeks, mice were imaged with a
LSM 7MP microscope (Zeiss) equipped with a water-immersion
objective (20×, NA = 1.0; Zeiss). Mice were anesthetized with
isoflurane (1%–1.2% in 95% O2 and 5% CO2), placed on a
heating pad and fixed to a custom-made holder using the
attached metal bar. eGFP was excited with a femtosecond laser
(Mai Tai DeepSee, Spectra Physics) at a wavelength of 920 nm.
Apical dendritic tufts of layer V pyramidal neurons in the
somatosensory cortex were imaged in consecutive sessions every
week. Three imaging positions per animal were chosen, with
up to ten dendrites per region of interest. Each imaging session
did not last more than 60 min. The same imaging position was
retrieved based on the vascular pattern of the cortex and the
stable branch points of apical dendritic shafts. For overview
images, z-stacks of 300 µm depth with 3 µm axial resolution
and 1024 × 1024 pixels per image frame (0.4 µm/pixel)
were acquired. For dendritic spines, high-resolution images
were taken with 1 µm axial resolution and 512 × 256 pixels per
image frame (0.1 µm/pixel). To keep the emitted fluorescence
stable at different depths and also at subsequent imaging sessions,
the z-correction tool in the microscope control software was
used, which allows an adjustment of the laser intensity.
Analysis of Dendritic Spine Plasticity
Dendritic spines were counted manually in ZEN 2011 (Zeiss).
Due to small movements artifacts of the tissue e.g., because of
pulsation of nearby capillaries, images were analyzed in three
dimensions and not in z-projections. All clear spines emanating
laterally from the dendritic shaft, regardless of apparent shape,
with a length of>0.4 µm (Holtmaat et al., 2009) were measured.
Spines were counted as stable when they were detected at the
first time point of the imaging period, as well as a week later at
the same place, not >0.5 µm away from the previous position.
Lost spines were counted as lost when they consisted of<0.4 µm
length and as gained when they consisted of >0.4 µm in
length protruding from the dendrite. This scoring method has
already been used successfully (Holtmaat et al., 2005; Fuhrmann
et al., 2007). Because of resolution limitations in the z-plane,
only spines emanating from the dendrite in the x-y direction
were counted. As defined by Holtmaat et al. (2005), spines are
classified as transient if they last less than 4 days. However, in
the current study dendritic spine kinetics were evaluated on a
weekly basis. With respect to the longer imaging interval we
thus considered spines with a lifetime of less than 7 days as
transient. Daily turnover rate, representing the gain and loss
of spines from day to day, was calculated as following: (Ngained
+ Nlost)/(2 × Ntotal)/It, where Ngained is the number of gained
spines, Nlost is the number of lost spines, Ntotal is the number
of all apparent spines at a time point, and It is the number of
days between subsequent imaging sessions (Holtmaat et al., 2005;
Fuhrmann et al., 2007). Five animals per group and ten dendritic
segments of approximately 22–35 µm length were analyzed per
mouse.
Statistics
Statistics were calculated in GraphPad Prism 5.04 (GraphPad
Software, San Diego, CA, USA). Intergroup comparisons were
performed using two-tailed Student’s t-test. Dendritic spine
dynamics from day 1 until the end of the treatment (day 0–28)
were compared using two-way ANOVA treatment main factor
with Bonferroni post-hoc test. All results were normalized and
are presented as mean± SEM. Column factor p values< 0.05 are
defined as statistically significant.
RESULTS
MK-8931 Treatment Reduces Aβ40 Levels
in Mouse Cortex
Preclinical data has shown that the orally administered
BACE1 inhibitor MK-8931, crosses the blood-brain barrier and
remains stable in the brain up to 12 h in rats (Forman et al.,
2012; Kennedy et al., 2016). Chronic treatment with 12 and
40 mg/kg MK-8931 resulted in a dose-dependent reduction in
cerebrospinal fluid (CSF) Aβ levels after 12 h, of 40% and 80%
respectively, in mild-to-moderate AD patients (Forman et al.,
2013; Andrew Stamford, 2015) and in the transgenic AD mouse
model Tg2576 (Villarreal et al., 2017).
To verify these findings, we measured acute Aβ40 levels in
the cerebral cortex in four C57BL/6J wildtype mice after 4 h
of treatment with a single dose of 20 mg/kg of MK-8931 or
vehicle. ELISA measurements of brain homogenates showed that
MK-8931 treatment reduced Aβ40 levels by 47%± 4% compared
to vehicle treatment (t(6) = 9.5, p < 0.0001, unpaired t-test,
Figure 1).
MK-8931 Treatment Alters Dendritic Spine
Formation
Prior studies with two different BACE1 inhibitors showed a
significant decrease in the fraction of newly gained spines,
implicating an important role for BACE1 in promoting dendritic
spine development (Filser et al., 2015). To investigate, if
similar effects could be observed with the clinically most
advanced BACE1 inhibitor MK-8931, we recorded the structural
dynamics of apical dendritic spines of layer V pyramidal cells
in the somatosensory cortex of adult GFP-M mice treated
with MK-8931, by chronic in vivo two-photon microscopy
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FIGURE 1 | MK-8931 (20 mg/kg) treatment significantly reduced Aβ 40 levels
in the murine cortex (t(6) = 9.5, p < 0.0001, two-tailed unpaired Student’s
t-test). Brain samples were taken 4 h after acute treatment and were analyzed
by Sandwich-ELISA assay. Data presented as mean ± SEM, n = 4.
(Figures 2A,B). The treatment period with MK-8931 (20 mg/kg,
every 12 h) as well as vehicle lasted for 21 days.
As anticipated, we observed a significant decrease of
6% ± 1.4% (F(1,8) = 59.36, p < 0.0001, ANOVA treatment
main factor, Figure 2B) in total spine density after 21 days
of MK-8931 treatment. Furthermore, MK-8931 treatment
strongly affected the formation of dendritic spines. The fraction
of new spines decreased by 50% ± 8.2% (F(1,8) = 11.02,
p = 0.0105, ANOVA treatment main factor) after 21 days
of BACE1 inhibitor treatment compared to the vehicle group
(Figure 2C). BACE1 inhibition also decreased significantly
the fraction of lost spines, although to a smaller degree, by
29%± 10.3% (F(1,8) = 10.52, p = 0.0118, ANOVA treatment main
factor, Figure 2D).
These observations confirmed a critical function of BACE1 in
the regulation of dendritic spine formation.
MK-8931 Treatment Does Not Cause Spine
Elimination
Next, we investigated whether BACE1 inhibition has an effect on
spine stability in the somatosensory cortex.
We analyzed daily spine turnover rates in MK-8931 treated
mice and detected a significant decrease by 42% ± 8.8%
(F(1,8) = 17.05, p = 0.0033, ANOVA treatment main factor,
Figure 3A). To analyze the decrease in spine turnover in more
detail, we quantified the density of transient and stable spines
before, during and after the treatment period. No significant
effect on stable spine density was detected (F(1,8) = 2.14,
p = 0.1817, ANOVA treatment main factor, Figure 3C),
whereas the density of transient spines decreased significantly by
41% ± 11.5% (F(1,8) = 7.38, p = 0.0264, ANOVA treatment main
factor, Figure 3B).
Furthermore, we analyzed the survival rate of newly gained
spines. We observed an apparent but statistically non-significant
decrease in MK-8931 treated mice (t(8) = 0.9, p = 0.395,
unpaired Student’s t-test, Figure 3D). After termination of
BACE1 inhibitor treatment we recognized a recovery in spine
density, gained and transient spines, as well as in daily spine
turnover rate. These parameters did not differ significantly
between both cohorts at imaging day 42, while the fraction of
lost spines remained significantly reduced in the inhibitor treated
group (p = 0.015, unpaired Student’s t-test). In summary, our
data showed that BACE1 inhibition specifically altered dendritic
spine formation. Thus, the reduction of dendritic spine density
in MK-8931 treated mice was caused by diminished formation of
new spines, whereas spine stability was not affected.
DISCUSSION
In the present study, we demonstrated that chronic treatment
with the BACE1 Inhibitor MK-8931 reduced total dendritic
spine density of layer V pyramidal cells in the somatosensory
cortex of adult mice. To unravel the mechanistic cause of this
phenotype we applied intravital microscopy and analyzed the
kinetics of structural spine plasticity. Our data showed that
MK-8931 treatment specifically reduced the formation rate of
new dendritic spines in a reversible manner, but did not cause an
elimination of stable spines. Therefore, MK-8931 treatment does
not alter the overall structural integrity of excitatory synapses.
In contrast, γ-secretase inhibitor application has been shown
to cause elimination of stable spines with a persistent reduction
in spine density in vivo (Bittner et al., 2009). Furthermore,
genetic ablation of the γ-secretase substrate Notch1 in pyramidal
CA1 neurons alters spine density as well as spine morphology
and leads to deficits in learning and short-term memory
(Alberi et al., 2011). Accordingly, treatment with the γ-secretase
inhibitor LY-450139 led to worsening of cognitive functions in
AD patients and thus failed in clinical phase III trials (Schor,
2011; Doody et al., 2013; Funded by Eli Lilly, ClinicalTrials.gov,
number: NCT00594568).
The mechanism-based side effects of BACE1 inhibition
on dendritic spines are thus more subtle compared to
γ-secretase inhibition. However, although the most promising
BACE1 inhibitor MK-8931 effectively lowered Aβ CSF levels
in healthy adults and showed no obvious side effects (Forman
et al., 2013), it failed in phase III clinical trials. The treatment
with MK-8931 failed to significantly slow down the disease
progression in mild to moderate AD patients and also had no
Frontiers in Aging Neuroscience | www.frontiersin.org 4 July 2018 | Volume 10 | Article 229
Blume et al. MK-8931 Alters Spine Formation
FIGURE 2 | BACE1 inhibitor MK-8931 altered plasticity of dendritic spines in vivo. (A) Micrographs of eGFP-labeled apical dendrites of layer V pyramidal neurons in
somatosensory cortex before, during and after administration of vehicle or MK-8931. Treatment started 8 days after first imaging timepoint and was continued over
21 days, every 12 h. White arrowheads exemplarily mark representative spines which were stable over the entire imaging period. Newly gained spines are labeled
with green arrowheads and lost spines are labeled with magenta arrowheads. (B) Quantification of spine density (C,D) fraction of gained and lost spines in mice
treated with vehicle or MK-8931 (20 mg/kg). N = 5 animals per group, n = 10 dendrites per animal. Data is presented as mean ± SEM. Bonferroni post-hoc test
results: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 from two-way ANOVA (day 0–28).
FIGURE 3 | MK-8931 treatment did not cause spine elimination. (A) Spine stability and turnover rates in vehicle and MK-8931 treated mice. Daily turnover rate
significantly decreased at the end of inhibitor treatment. (B,C) MK-8931 treatment significantly decreased density of transient spines, whereas density of stable
spines was not affected. Bonferroni post-hoc test: ns: p = 0.4926, ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 (two-way ANOVA between day 0–28). (D) Survival rate
of newly gained spines was not affected by BACE1 inhibitor treatment. N = 5 animals per group, n = 10 dendrites per animal. Two-tailed Student’s t-test, t(8) = 0.9,
p = 0.394. Data presented as mean ± SEM.
positive effect in prodromal AD patients (Hawkes, 2017; Egan
et al., 2018). These observations suggest that BACE1 inhibitor
treatment should begin even earlier, preferably at a stage when
individuals are still cognitively normal, to provide clinical
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benefit. This claim is supported by a recently published in vivo
animal study showing that BACE1 inhibitor treatment does
not completely stop the growth of established plaques but
strongly prevents the formation of new plaques (Peters et al.,
2018).
Thus, early pharmacological intervention in a timely manner
seems more promising to halt the pathological cascade leading to
AD. However, although short-term BACE1 inhibitor treatment
seems to be well tolerated, even subtle side effects might
culminate in a detrimental outcome if BACE1 inhibition persists
over many years. In this context it has to be considered that
Aβ, at physiological levels, plays an essential role in synaptic
plasticity and memory (Dawson et al., 1999; López-Toledano
and Shelanski, 2004; Laird et al., 2005; Zou et al., 2016).
In particular Puzzo et al. (2008) showed, that application of
physiological doses of Aβ42 monomers and oligomers evokes a
significant increase in synaptic long-term potentiation, whereas
high Aβ levels reduce hippocampal long-term potentiation.
Furthermore, BACE1 is involved in the proteolytic processing of
the transmembrane protein neuregulin 1 (Nrg1). The N-terminal
cleavage products of Nrg1 activates receptor tyrosine kinase
ErbB dependent signaling pathways with numerous roles in CNS
development and functions, like synapse formation, plasticity
and axon myelination (Falls, 2003; Michailov et al., 2004;
Savonenko et al., 2008). Therefore, it will be necessary to
determine the optimal inhibitor dosage to avoid side effects on
dendritic spines and thus balance clinical safety and efficacy.
Indeed, BACE1 inhibitor induced effects on dendritic spine
formation have been shown to be dose dependent. While
low- and high-dosed inhibitors both significantly reduce Aβ
levels in murine brains, application of low-dosed inhibitor has
no effect on structural dendritic spine plasticity (Filser et al.,
2015). Interestingly, it was recently shown that pharmacological
BACE1 inhibition reduces dendritic spine density via Seizure
Protein 6 (Sez6; Zhu et al., 2018). Sez6 is exclusively cleaved by
BACE1 and required for normal dendritic arborization as well as
synaptic plasticity (Gunnersen et al., 2007; Pigoni et al., 2016).
Since soluble Sez6 is detectable in CSF (Khoonsari et al., 2016),
it might serve as a biomarker to evaluate the BACE1 inhibitor
dosage, which is sufficient to preserve the synaptic function of
BACE1.
In summary, our results show that the BACE1 inhibitor
induced reduction in dendritic spine density is not caused
by the elimination of existing spines, but by a reduced spine
formation, which is reversible after cessation of BACE1 inhibitor
treatment. Therefore, the mechanism-based side effects of
BACE1 inhibition on synaptic function are less severe compared
to γ-secretase inhibition and could be potentially avoided by
monitoring Sez6 in CSF, which is exclusively cleaved by BACE1,
to evaluate the optimal inhibitor dosage.
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